Sample management provider, REMP, announced the introduction of its
REMP Small Size Store (SSS), a fully automated sample storage and
retrieval system that incorporates 'cherry picking,' enabling
reliable retrieval of samples...
Gentel Biosurfaces have signed a supply and marketing license
agreement with Kreatech Biotechnology to regarding the sales of ULS
reagents for protein labelling and use on single capture antibody
chips.
Biovitrum and Santhera have announced the signing of an exclusive
license and collaboration agreement, which aims to develop DPP-IV
inhibitors for the treatment of type 2 diabetes and other metabolic
diseases.
Micro-particle specialists, rap.ID, are set to expand its new
laboratory premises to meet the demands of contamination-free
particle identification. The move is in response to the increase in
demand for qualified particle counts and...
Kreatech Biotechnology launches a series of nucleic acid labelling
kits for in situ hybridisation and filter hybridisation
applications. These kits offer the researcher the possibility to
non enzymatically label their target nucleic...
Tripos introduces its LeadDiscovery program to accelerate the drug
discovery process. The new program offers a method to develop novel
preclinical compounds for customers in the pharmaceutical and
biotechnology industry.
German biotech company, Orthogen, has presented a study that has
shown the emergence of autologous bioengineered proteins as a
viable alternative to the cox-II inhibitor class. The class of drug
was blighted with severe side effects,...
LION bioscience made a big step towards profitability, as ongoing
restructuring plans appear to be reaping rewards. The decision to
sell off its troublesome bioinformatics unit appears wise as the
company reached a near break-even...
Santhera Pharmaceuticals and the Takeda Pharmaceutical Company have
established a collaboration to develop and market the first
treatment for Friedreich's Ataxia - a genetic condition that
impacts quality of life substantially...
Researchers have discovered a new tumour defence system that
interferes with the cells that are trying to kill them. These
results raise the possibility of new drug targets for cancer such
as those that may transport free fatty acids...
Scientists have discovered the genetic pathway responsible for
breast cancer growth, which details how the female hormone
oestrogen causes growth of breast cancer cells. In practical terms,
efforts can now be focused on developing...
According to a new report, the advancement of ADME/Tox technologies
will give rise to considerable time and cost savings as early
screening and increasingly innovative solutions continue to
underline the importance of this technology...
Researchers have discovered that a protein, which acts as a
fundamental inhibitor of cell movement or migration, may be a
likely target for new drug development aimed at decreasing tumour
metastasis, or spread, throughout the body.
The raft of pharmaceutical companies reporting results for the
second quarter of 2005 provided mixed indications as to the state
of the industry. The claim that pipeline product fruition is
beginning to return among the pharmaceutical...
Scientists have admitted that women who take heart drugs are taking
unknown risks after a review of existing data has shown that these
drugs can affect women differently.
A new genome sequencing technique that claims to be 100 times
faster than previous technologies has been developed by 454 Life
Sciences Corporation. The technique is the first new technology for
genome sequencing to be developed and...
The possibilities nanotechnology has in drug and therapeutic
applications was demonstrated once again after researchers were
able to demonstrate the destruction of cancer cells whilst keeping
healthy tissue unharmed.
Bruker Biosciences returned back to profitability after a difficult
12 months, posting a modest revenue increase for the second
quarter. This has been driven by the introduction of new and
established technologies including its AXS...
Living Cell Technologies announced a significant reduction in the
size of brain lesions in a Huntington's disease (HD) model after
pre-clinical demonstrated this result using its NeurotrophinCell
(NtCell).
Researchers have discovered a new mechanism that reveals how high
levels of a neurotransmitter exerts its effect on the brain. The
findings provide new research avenues to understand and potentially
manage neurotransmitter-related...
The future for Novartis' experimental cancer drug looked grim after
an ongoing clinical trial suggested that it was unlikely to boost
survival rates of patients with colon cancer. This is the second
setback for the drug this...
The Foundation for Innovative New Diagnostics (FIND) and Eiken
Chemicals have announced a collaboration to develop a rapid and
simple test for the detection of active tuberculosis (TB), a
disease that has infected close to a third...
A new device - dubbed an "optoelectronic tweezer," enables
researchers to manipulate large numbers of single cells and
particles using optical images projected onto a glass slide coated
with photoconductive materials. The...
Applied Biosystems Group reported a 40 per cent leap in profits as
the company released its forth quarter 2005 figures. The rise in
sales reflects the increased demand for biosecurity and human
identification products as well as its...
Invitrogen Corporation has acquired the publicly held life sciences
company BioSource International in a transaction totalling
approximately $130 million. This deal adds to Invitrogen's growing
collection of protein and primary...
Cara Therapeutics has announced positive results of a phase 1
clinical trial for its new class of peripherally acting kappa
opioid agonists currently under development for the treatment of
postoperative pain.
Global supplier of scientific instruments, Varian, have launched
its first premium shielded vertical high-resolution superconducting
magnets designed to reduce stray magnetic fields by up to fivefold
(in volume). Pharmaceutical and...
Johnson & Johnson Pharmaceutical Research and Development
(J&JPRD) and the Hurel Corporation have entered into a joint
scientific collaboration to develop microfluidic, technology, with
a view to launching the world's...
The first study of systemic siRNA efficacy at therapeutically
relevant doses has been published by Sirna Therapeutics, who have
demonstrated an almost complete reduction of the hepatitis B virus
(HBV). The study establishes a strong...
Acambis has commenced clinical trials of its investigational
vaccine against Clostridium difficile (C. difficile) - a common
hospital-acquired infection, in which a new virulent strain has
emerged, causing sharp increases in the number...
NanoDrop Technologies has introduced a fluorospectrometer to its
line of analytical instruments that allow researchers to measure
ever-smaller sample amounts making it ideal for today's drug
research environment.
Scientists from the University of California have discovered three
molecules that show great potential in the development of new
Alzheimer's drugs. The new therapy targets a protein that
accumulates in Alzheimer's victims...
The world's biggest maker of birth-control pills, Schering AG, has
unveiled its second-quarter profit for 2005, which saw the
drugmaker's profits rise by 34 per cent, helped by sales of its
Yasmin contraceptive and gains...
Maxim Pharmaceuticals has been issued with a US patent that covers
a novel class of potent apoptosis inducers with vascular targeting
activity that inhibits microtubule formation - a prime drug target
in the fight against cancer.
Provectus Pharmaceuticals are to begin phase 1 clinical trials of
new cancer treatment, PV-10, the company's new drug candidate for
the treatment of metastatic melanoma (the most aggressive form of
skin cancer), in which 53,000...
Animal rights extremists sunk to a new low as Oxford University was
targeted in an arson campaign, which resulted in an estimated
£500,000 (€719 000) worth of damage to boats and property. The
attack was specifically intended to halt...
Japanese biopharmaceutical company Sosei, is to acquire UK-based
Arakis, in a £106.5 million deal that includes a £213 million ($375
million) global partnership with Novartis for its lead product, a
once daily, inhaled, long-acting...
BioGenex announces the launch of the Xmatrx, a walk-away system for
automation of FISH, ISH, and IHC for molecular diagnostics and
therapeutic target identification and validation as well as cell
and tissue staining applications,...
Manufacturing consolidation and acquisition costs helped reduce net
income as Millipore revealed its 2005 second quarter financial
results. The company has just completed the purchase of two
companies with the intention of increasing...
A first-in-class small molecule with a novel mechanism of action
that selectively induces cancer cell death is to undergo phase I
clinical trials. Its makers, Cylene Pharmaceuticals have claimed
the drug candidate has shown efficacy...
Sigma-Aldrich has launched a handful of laboratory equipment and
technological developments that could prove useful in drug
discovery. The life science company is currently in the midst of a
reorganisation of its operating structure...
Intermune and Array BioPharma have agreed to extend and expand
their current Hepatitis C (HCV) drug discovery collaboration. The
main area of focus, protease inhibitors, represents a promising
class of drugs for HCV because of its...
Swiss pharmaceutical firm Roche has acquired GlycArt Biotechnology
in an attempt to further strengthen Roche's capabilities in the
therapeutic antibody research sector, capitalising on their
pre-existing collaboration in September...
According to latest findings, the biotechnology/pharmaceutical
industry submitted 542 commercial Investigational New Drug (IND)
applications in 2004, increasing by more than a third from the
previous year.
Life sciences investment group Abingworth Management has announced
the initial Abingworth BioEquities Fund (ABE) has raised $53
million (€44 million) to invest across the life sciences field
including human therapeutics.
Scientists believe they may have found a way to prevent heart
failure associated with the genetic disease, Duchenne muscular
dystrophy (DMD). The study is the first to demonstrate a new,
promising approach to repairing the cardiac...
Nanion has launched the world's smallest first generation of
throughput optimised patch-clamp automats. This drug discovery
technology is based on a micro-structured chip, which facilitates
electrophysiological experiments for...
A particle finder, which can determine particle size, number and
shape within 15 seconds, has been launched by German equipment
supplier rap.ID, which believes such technology could solve the
problem of foreign particle contamination...
